PRIMAVIS 100 is a dihydrotestosterone derived anabolic
steroid. PRIMAVIS 100 contains
methenolone enanthate, a long-acting methenolone ester
producing a rapid onset of serum
methenolone with a continued duration of action of 5 to 7
days after IM injection. PRIMAVIS
100 is moderately anabolic with limited androgenic
properties. Methenolone cannot
aromatize to estrogen, reducing estrogenic side effects, and
has a favorable safety profile
among anabolic agents.
Anabolic steroids are synthetic derivatives of testosterone.
Certain clinical effects and
adverse reactions demonstrate the androgenic properties of
these drugs. Complete
dissociation of anabolic and androgenic effects has not been
achieved. The actions of
anabolic steroids are thus similar to those of male sex
hormones. Anabolic steroids
suppress the gonadotropic functions of the pituitary and may
exert a direct effect upon the
testes. During exogenous administration of anabolic
androgens, endogenous testosterone
release is inhibited through inhibition of pituitary
luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback
inhibition of pituitary folliclestimulating hormone (FSH). Methenolone is a
dihydrotestosterone derivative which cannot
be aromatized to estrogen and which acts upon the androgen
anabolism through increased nitrogen retention and protein
synthesis in muscle tissue.
Methenolone enanthate in a single dose pharmacokinetic study
has demonstrated a mean
elimination half-life of 6 days.
As an alternate or adjunctive therapy in patients for the
promotion of weight gain following
weight loss and/or muscular atrophy associated with
extensive surgery, chronic infections,
long term hospitalization, or severe trauma. To compensate
for protein catabolism
consequent to corticosteroid therapy.
DOSAGE AND ADMINISTRATION
Adult male: 100 – 200mg injected IM every 3 – 5 days for a
duration of 8 to 12 weeks.
Male: Gynecomastia, increased frequency of erections,
oligospermia, prostatic hypertrophy,increased risk of prostate
Skin and Appendages: Hirsutism, pattern baldness and acne,
Fluid/Electrolyte Disturbances: Retention of sodium,
chloride, water, potassium, calcium,
and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations
in liver function tests; rarely,
hepatocellular neoplasms, peliosis hepatitis, hepatic
adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII,
& X; bleeding in patients on anticoagulant therapy.
Nervous System: Increased or decreased libido, headache,
anxiety, depression, and
Metabolic: Reduced glucose tolerance and inhibition of
Other: Serum lipid changes, hypercalcaemia, hypertension,
oedema, and potentiation of
Patients with diagnosed or suspected carcinoma of the
prostate, breast, or testis.
Patients with diagnosed or suspected female breast carcinoma
with hypercalcemia as
androgenic agents may increase osteolytic bone resorption.
Women who are pregnant or may become pregnant because of
possible masculinization of
Patients with nephrosis or the nephrotic phase of nephritis.
Patients with hypercalcemia.
Hypersensitivity to this product or any of its ingredients.
Patients with pre-existing cardiac, renal, and/or hepatic
Discontinue treatment upon signs of jaundicing or
Because androgens may alter serum cholesterol concentration,
caution should be used
when administering these drugs to patients with a history of
myocardial infarction or
coronary artery disease.
Patients on oral anticoagulant therapy require close
monitoring especially when androgens
are started or stopped.
Diabetics: androgens may alter the metabolism of oral
hypoglycemic agents or may change
insulin sensitivity in patients with diabetes mellitus which
may require adjustment of dosage
of insulin and other hypoglycemic drugs.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit,
Hepatic function tests –
Prostatic specific antigen – PSA, Testosterone: total, free,
Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to
androgen use. Periodic evaluations of the prostate should
continue while on androgen
therapy, especially in patients with difficulty in urination
or with changes in voiding habits.
Oral hypoglycemic agents: may inhibit the metabolism of oral
hypoglycemic agents which
may require adjustment of dosage.
Anticoagulants: Patients on anticoagulants should be
carefully monitored during anabolic
steroid therapy as anabolic steroids may increase
sensitivity to oral anticoagulants. Patients
should be monitored regularly during anabolic steroid
therapy, particularly during initiation
and termination of therapy.
PRIMAVIS 100(100mg/ml )- 10 ampules of 1ml each.
|Each ml contains:|
|Metenolone Enanthate||100 mg|